Safety and Toxicity Data of Theracurmin®

The toxicity assessment and safety test results of our well-developed Theracurmin® are as follows.

Toxic Data

1. Ames test had been performed with the Salmonella spp. (4 strains) E. Coli and test shows result as negative.

2. Chromosome aberration tests have been performed in vitro chromosome aberration test in Chinese hamster lung cells and tests show results as negative.

3. Micronucleus assay tests have been performed with Male Sprague dewley rats bone marrow micronucles assay and again tests show results as negative.

4. Acute toxicity studies (Rats) performed with a dose of 1250,2500,5000mg/kg as curcumin 375,750,1500mg/kg once resulted in no toxicological findings observed by oral administration.

5. Subacute toxicity study (Rats) test performed with a dose of 0,625,1250,2500,5000mg/kg as curcumin 0,187.5,375,750,1500mg/kg with a period of 2 weeks resulted in no toxicological findings observed by oral administration.

6. Subchronic toxicity study (Rats) test performed with a dose of 0,1250,2500,5000mg/kg as curcumin 0,375,750,1500mg/kg with a period of 13 weeks resulted in no toxicological findings observed by oral administration.



q.d.: Once a day
p.o.: Oral intake
ADI: Acceptable Daily Intake
Standard Dosage: 180mg/day (as curcumin)= ADI: 3mg/kg x 60kg (average adult body weight)

Takahashi T, Iio S, Takara T. Safety Evaluation of TheracurminTM in Healthy Japanese Adults. ―A Randomized, Double—blind, Placebo—controlled Parallel—group Study― Jpn Pharmacol Thervol. 2019 Jul 1; 47(7): 1097-1113.


Small GW, Siddarth P, Li Z, Miller KJ, Ercoli L, Emerson ND, Martinez J, Wong KP, Liu J,Merrill DA, Chen ST, Henning SM, Satyamurthy N, Huang SC, Heber D, Barrio JR. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. Am J Geriatr Psychiatry. 2018 Mar; 26 (3): 266-277.